Table 6 Data use to address specific research questions. Key research questions in the INOVATION program mapped to specific measurement tools used to address each question

(1) Can blinatumomab be adapted for LMIC settings, and is it feasible, acceptable, and appropriate?

1) Implementation outcomes assessments (FIM, AIM, IAM, cost)

2) Semi-structured interviews

3) Program evaluation group interview

(2) Does an adapted multidisciplinary training program improve these implementation outcomes?

1) Knowledge assessments

2) Implementation outcomes assessments (FIM, AIM, IAM, cost)

(3) Are there contextual factors (readiness, capacity, perceived complexity) that correlate with successful implementation?

1) Hospital assessment questionnaire

2) Barrier assessments: complexity assessment, ICS, ORIC

3) Implementation outcomes assessments (FIM, AIM, IAM)

4) Semi-structured interviews

(4) What are the key strategies as perceived by stakeholder groups and are these the same between different groups?

1) Implementation strategy feedback

2) Program evaluation group interview

(5) What is stakeholder satisfaction with this implementation-guided approach?

1) Semi-structured interviews with implementation teams

2) Program evaluation group interview

(6) Is the effectiveness of this adapted administration of blinatumomab the same as what has been documented in high-income settings?

1) Patient enrollment information

2) Patient safety record: adverse event reporting

3) Management records: interruption record

4) Clinical outcome data